insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Isolated oral CD30/CD4 CAR T cell lymphoma in long-term remission after radiotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy 2025 Vol.33(12) p. 6033-6040

Bezerra E, Lupu L, de Lima M, Pfaller L, Neal A, Hajizadeh NR, Zhao Q, Beibel M, Chung C, Lemmens M, Sim A, Oertli M, Voorhees T, Bohnert R, Denlinger N, Gilbart Y, Bontadelli L, Monovich L, Willert J, Stover D, Gao J, Li L, Reinker S, Naumann U, Menssen HD, Jones D, Libertini S, Brammer JE

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

A chimeric antigen receptor (CAR) CD30/CD4 T cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T cell-based therap

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Bezerra E, Lupu L, et al. (2025). Isolated oral CD30/CD4 CAR T cell lymphoma in long-term remission after radiotherapy.. Molecular therapy : the journal of the American Society of Gene Therapy, 33(12), 6033-6040. https://doi.org/10.1016/j.ymthe.2025.08.043
MLA Bezerra E, et al.. "Isolated oral CD30/CD4 CAR T cell lymphoma in long-term remission after radiotherapy.." Molecular therapy : the journal of the American Society of Gene Therapy, vol. 33, no. 12, 2025, pp. 6033-6040.
PMID 40903902
DOI 10.1016/j.ymthe.2025.08.043

Abstract

A chimeric antigen receptor (CAR) CD30/CD4 T cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T cell-based therapy. The TCL showed lentiviral integration in ANKHD1-EIF4EBP3, loss of function of TET2, and NTRK1 copy number gain, suggesting that genetic alterations unrelated to insertional mutagenesis contributed to lymphomagenesis. The patient remains in remission 2 years after radiotherapy. This is the only CARTCL case reported at the Ohio State University James Comprehensive Cancer Center out of 288 patients treated with CAR-T cells.

MeSH Terms

Humans; CD4-Positive T-Lymphocytes; Immunotherapy, Adoptive; Ki-1 Antigen; Lymphoma, T-Cell; Receptors, Chimeric Antigen; Remission Induction; Treatment Outcome